Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) - an Open-Label Extension to the TACTT3 Study

NCT02040207 is registered in ClinicalTrials.gov with Auris Medical AG as lead sponsor.

NCT NCT02040207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02040207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) - an Open-Label Extension to the TACTT3 Study
Lead sponsor
Auris Medical AG
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2014
Completion date
December 31, 2016
Enrollment
487 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tinnitus